Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.65 |
| ▸ | MMP13 | P45452 | 8/20 | 0.65 |
| ▸ | MMP3 | P08254 | 7/20 | 0.65 |
| ▸ | MMP1 | P03956 | 3/20 | 0.65 |
| ▸ | MMP9 | P14780 | 2/20 | 0.65 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28641212 | 0.84 | ALDH1A1 (0.62) | MMP2MMP13MMP3ALDH1A1PKM | |
| SCHEMBL26234061 | 0.83 | ALDH1A1 (0.50) | MMP2MMP13MMP3ALDH1A1PKM | |
| SCHEMBL7898412 | 0.80 | MMP2 (0.68) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL30667707 | 0.80 | CA12 (0.58) | MMP2MMP13MMP3ALDH1A1POLB | |
| SCHEMBL7899813 | 0.80 | MMP2 (0.56) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7516814 | 0.79 | MMP13 (1.00) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7502269 | 0.78 | MMP13 (0.86) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL3091205 | 0.77 | ALDH1A1 (0.59) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7502278 | 0.73 | MMP13 (0.55) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL8446269 | 0.73 | MEP1B (0.58) | MMP2MMP13MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2008024784-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP11, MMP13 | MMP2 14/4885MMP13 3/4885MMP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.